<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124500">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02058173</url>
  </required_header>
  <id_info>
    <org_study_id>HP7-92</org_study_id>
    <secondary_id>HP7-92</secondary_id>
    <nct_id>NCT02058173</nct_id>
  </id_info>
  <brief_title>&quot;Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study&quot;</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee and Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Chloroquine comparing with placebo
      for treatment of non- response HCV patients.. In this triple blind pilot study, 20 patients
      with confirmed chronic hepatitis C will be randomize into treatment group (Chloroquine 150
      mg daily, for 8  weeks) or control group (placebo once daily, for 8  weeks). Patients who
      have receiving anti neoplastic, anti viral or Immunomedullator drugs during 6 months prior
      to study, have co-infection Hepatitis A,C,D or HIV, severe liver or renal dysfunction, are
      pregnant or breast fed, or refuse to sign informed consent will be excluded.. At the end of
      therapy (12 weeks) and at baseline, first, second and third month after receiving drug and
      placebo HCV Virus load, CBC LFT and biochemical parameters  will be evaluated and compared
      between groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Loss of HCV RNA at end of treatment which is 8 weeks</measure>
    <time_frame>march 2014</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Two log decrease in HCV RNA at the end of treatment</measure>
    <time_frame>july 2014</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>ALT response which is significant decrease in ALT-(biochemical response during Treatment)</measure>
    <time_frame>july 2014</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>chloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg chloroquine and lacebo , one tablet daily for 2 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg chloroquine and lacebo , one tablet daily for 2 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150 mg/daily chloroquine compare to placebo for 12 week</intervention_name>
    <arm_group_label>chloroquine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <arm_group_label>chloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of
             treatment

          -  who never achieved undetectable HCV RNA during treatment of a minimum duration of 24
             weeks

        Exclusion Criteria:

          -  Receiving anti neoplasm, anti viral or immunomedulator drugs during 6 months prior to
             study

          -  coinfection with Hepatitis A,C,D viruses or HIV

          -  Severe dysfunction of liver and kidney

          -  pregnancy

          -  breast feeding

          -  refusing to give informed consent

          -  active Alcohol user

          -  presence of decompensate cirrhosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamran B Lankarani, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Health policy research center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamran Bagheri Lankarani, M.D</last_name>
    <phone>098+-711-2309615</phone>
    <email>lankarani@mohme.gov.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Health Policy Research Center</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamran B Lankarani, M.D</last_name>
      <phone>098-711-2309615</phone>
      <email>lankarani@mohme.gov.ir</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Payam Peymani</investigator_full_name>
    <investigator_title>PhD Student of pharmacoepidemiology,health policy reseach center,Shiraz University of Medical Sciences</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
